ReviewMolecular biology reports2026
Lipid metabolism and chromatin-associated sirtuin-dependent epigenetic reprogramming in cancer.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipids are essential components of cancer biology, serving not only as sources of energy and biomass but also as signalling molecules that influence gene regulation and cellular plasticity. Increasing evidence suggests that lipid metabolic rewiring can shape epigenetic states through the activity of sirtuins, a family of NAD+-dependent enzymes with deacetylase, deacylase and ADP-ribosyltransferase activities that couple metabolic cues to chromatin regulation. This narrative review examines how alterations in fatty acid oxidation, lipid uptake, cholesterol metabolism and lipid-derived metabolites converge on the sirtuin family of NAD+-dependent enzymes to regulate epigenetic states in cancer. Lipid metabolism shapes sirtuin function by influencing NAD+/NADH balance, acetyl-CoA availability and the production of diverse acyl-CoA species, thereby modulating histone acetylation, non-canonical lysine acylations and DNA methylation programmes. In parallel, lipid metabolites can directly regulate sirtuin abundance, activity and subcellular localization, with context-dependent consequences for chromatin regulation and transcriptional plasticity. Emerging evidence indicates that this lipid-sirtuin-epigenetic axis contributes to metabolic adaptation and tumour cell fitness, stemness, antitumour immunity and metastatic dissemination. The dual nature of sirtuin signalling is also discussed, as these enzymes can either promote or constrain tumour progression depending on the metabolic and microenvironmental context. Therapeutic opportunities targeting lipid metabolism and sirtuins are considered, together with the potential of lipid, sirtuin and epigenetic signatures as biomarkers for prognosis, patient stratification and precision oncology.
Indexed as
Identifiers
42640355What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.